The Pharma Letter4h
ALX Oncology says evorpacept scores well in Phase II study
US clinical-stage immuno-oncology biotech ALX Oncology Holdings released positive updated data from the ASPEN-06 Phase II ...
The Pharma Letter3h
BIOVIIIx unit deal with TagCyx to create new company
Naples, Italy-based rare diseases focused biotech BIOVIIIx says that its subsidiary Anbition and Japanese firm TagCyx ...